Jacob Berchuck
- Department of Hematology and Medical Oncology
Assistant Professor
- (404) 727-8253
- jberchuck@emory.edu
Overview
Jacob Berchuck, MD, is a board-certified medical oncologist specializing in the treatment of genitourinary cancers. Dr. Berchuck is an attending physician at Winship Cancer Institute of Emory University and an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Before joining Emory in 2024, Dr. Berchuck was a genitourinary oncologist at Dana-Farber Cancer Institute.
Dr. Berchuck earned his MD from Duke University in Durham, North Carolina. He completed his residency in internal medicine at the University of California, San Francisco, and his fellowship in hematology/oncology, along with a postdoctoral research fellowship, at Dana-Farber Cancer Institute/Harvard Medical School.
Dr. Berchucks primary clinical and scholarly focus includes developing biomarkers to guide treatment decisions, deciphering mechanisms of treatment resistance and discovering novel therapeutic strategies. His research predominantly focuses on liquid biopsies studying tumor biology by profiling cell-free DNA circulating in the bloodstream aiming for a future where a simple blood draw can provide real-time insights to choose the right treatment for the right patient at the right time.
Dr. Berchucks articles have been published in several leading journals, including Cancer, Nature Medicine, the New England Journal of Medicine and JAMA Oncology.
Academic Appointment
- Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Duke University
Research
Publications
-
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.
Nat Commun Volume: 16 Page(s): 1779
02/19/2025 Authors: Mitchell J; Camacho N; Shea P; Stopsack KH; Joseph V; Burren OS; Dhindsa RS; Nag A; Berchuck JE; O'Neill A -
Unearthing a Prostate Cancer cfDNA Signature that "Stems" from AR Alterations.
Clin Cancer Res Volume: 31 Page(s): 7 - 9
01/06/2025 Authors: Nawfal R; El Hajj Chehade R; Berchuck JE -
Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer.
Clin Cancer Res Volume: 31 Page(s): 122 - 129
01/06/2025 Authors: Stopsack KH; Vijai J; Conry M; Berchuck JE; Kemel Y; Vasselman SE; Freeman DA; Lee G-SM; Mandelker D; Solit DB -
A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
Prostate Volume: 84 Page(s): 1479 - 1489
12/01/2024 Authors: Boiarsky D; Tewari AK; Gulhan DC; Bakouny Z; Ananda G; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Choueiri TK -
Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
Clin Cancer Res Volume: 30 Page(s): 3798 - 3811
09/03/2024 Authors: El Zarif T; Meador CB; Qiu X; Seo J-H; Davidsohn MP; Savignano H; Lakshminarayanan G; McClure HM; Canniff J; Fortunato B -
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
Nat Med Volume: 30 Page(s): 907
03/01/2024 Authors: Baca SC; Seo J-H; Davidsohn MP; Fortunato B; Semaan K; Sotudian S; Lakshminarayanan G; Diossy M; Qiu X; El Zarif T -
Liquid biopsy epigenomic profiling for cancer subtyping.
Nat Med Volume: 29 Page(s): 2737 - 2741
11/01/2023 Authors: Baca SC; Seo J-H; Davidsohn MP; Fortunato B; Semaan K; Sotudian S; Lakshminarayanan G; Diossy M; Qiu X; El Zarif T -
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.
Cancer Discov Volume: 13 Page(s): 632 - 653
03/01/2023 Authors: De Sarkar N; Patton RD; Doebley A-L; Hanratty B; Adil M; Kreitzman AJ; Sarthy JF; Ko M; Brahma S; Meers MP -
Differential responses to taxanes and PARP inhibitors in ATM-versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Prostate Volume: 83 Page(s): 227 - 236
02/01/2023 Authors: Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N -
Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.
Nat Commun Volume: 14 Page(s): 346
01/21/2023 Authors: Nassar AH; Abou Alaiwi S; Baca SC; Adib E; Corona RI; Seo J-H; Fonseca MAS; Spisak S; El Zarif T; Tisza V